These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38880808)

  • 1. Targeted therapy for capillary-venous malformations.
    Zerbib L; Ladraa S; Fraissenon A; Bayard C; Firpion M; Venot Q; Protic S; Hoguin C; Thomas A; Fraitag S; Duong JP; Kaltenbach S; Balducci E; Lefevre C; Villarese P; Asnafi V; Broissand C; Goudin N; Nemazanyy I; Autret G; Tavitian B; Legendre C; Arzouk N; Minard-Colin V; Chopinet C; Dussiot M; Adams DM; Mirault T; Guibaud L; Isenring P; Canaud G
    Signal Transduct Target Ther; 2024 Jun; 9(1):146. PubMed ID: 38880808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpelisib administration reduced lymphatic malformations in a mouse model and in patients.
    Delestre F; Venot Q; Bayard C; Fraissenon A; Ladraa S; Hoguin C; Chapelle C; Yamaguchi J; Cassaca R; Zerbib L; Magassa S; Morin G; Asnafi V; Villarese P; Kaltenbach S; Fraitag S; Duong JP; Broissand C; Boccara O; Soupre V; Bonnotte B; Chopinet C; Mirault T; Legendre C; Guibaud L; Canaud G
    Sci Transl Med; 2021 Oct; 13(614):eabg0809. PubMed ID: 34613809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic landscape of common venous malformations in the head and neck.
    Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA
    J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
    Venot Q; Blanc T; Rabia SH; Berteloot L; Ladraa S; Duong JP; Blanc E; Johnson SC; Hoguin C; Boccara O; Sarnacki S; Boddaert N; Pannier S; Martinez F; Magassa S; Yamaguchi J; Knebelmann B; Merville P; Grenier N; Joly D; Cormier-Daire V; Michot C; Bole-Feysot C; Picard A; Soupre V; Lyonnet S; Sadoine J; Slimani L; Chaussain C; Laroche-Raynaud C; Guibaud L; Broissand C; Amiel J; Legendre C; Terzi F; Canaud G
    Nature; 2018 Jun; 558(7711):540-546. PubMed ID: 29899452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
    Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E
    Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive phenotypic and genomic characterization of venous malformations.
    Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
    Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and Emerging Targeted Therapies for Vascular Malformations.
    Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
    Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic Loss-of-Function PIK3R1 and Activating Non-hotspot PIK3CA Mutations Associated with Capillary Malformation with Dilated Veins (CMDV).
    De Bortoli M; Queisser A; Pham VC; Dompmartin A; Helaers R; Boutry S; Claus C; De Roo AK; Hammer F; Brouillard P; Abdelilah-Seyfried S; Boon LM; Vikkula M
    J Invest Dermatol; 2024 Sep; 144(9):2066-2077.e6. PubMed ID: 38431221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic PIK3CA mutations as a driver of sporadic venous malformations.
    Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J
    Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.
    Morin G; Degrugillier-Chopinet C; Vincent M; Fraissenon A; Aubert H; Chapelle C; Hoguin C; Dubos F; Catteau B; Petit F; Mezel A; Domanski O; Herbreteau G; Alesandrini M; Boddaert N; Boutry N; Broissand C; Han TK; Branle F; Sarnacki S; Blanc T; Guibaud L; Canaud G
    J Exp Med; 2022 Mar; 219(3):. PubMed ID: 35080595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations in vascular malformations.
    Castillo SD; Baselga E; Graupera M
    Curr Opin Hematol; 2019 May; 26(3):170-178. PubMed ID: 30855339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
    Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
    Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity.
    Sterba M; Pokorna P; Faberova R; Pinkova B; Skotakova J; Seehofnerova A; Blatny J; Janigova L; Koskova O; Palova H; Mahdal M; Pazourek L; Jabandziev P; Slaby O; Mudry P; Sterba J
    Sci Rep; 2023 Jun; 13(1):10499. PubMed ID: 37380669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetics of vascular birthmarks.
    Mahajan P; Bergstrom KL; Phung TL; Metry DW
    Clin Dermatol; 2022; 40(4):313-321. PubMed ID: 35181412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A xenograft model for venous malformation.
    Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
    Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
    Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP
    Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
    Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
    Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
    JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PIK3CA mutation in an acquired capillary malformation.
    Rosenthal J; Sibbald C; Jen M; Deardorff MA; Treat J
    Pediatr Dermatol; 2020 Jan; 37(1):246-247. PubMed ID: 31830321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical management of vascular anomalies of the head and neck.
    Léauté-Labrèze C
    J Oral Pathol Med; 2022 Nov; 51(10):837-843. PubMed ID: 35668029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.